A Case of Pustular Psoriasis Developed during Infliximab Treatment for Crohn's Disease / 대한피부과학회지
Korean Journal of Dermatology
;
: 810-813, 2012.
Artículo
en Coreano
| WPRIM
| ID: wpr-90377
ABSTRACT
Infliximab is a monoclonal antibody that binds and inactivates tumor necrosis factor-alpha. It has been successfully used to manage diseases associated with a Th1 profile such as psoriasis, Crohn's disease, and rheumatoid arthritis. A 15-year-old boy presented for erythematous scaly papules and pustules with crust on his entire body, which had appeared initially 2 months ago. He had been treated with infliximab for Crohn's disease during the last 14 months and had not been diagnosed with psoriasis. A skin biopsy specimen demonstrated papulosquamous dermatitis with subcorneal pustule formation, suggestive of pustular psoriasis. The patient was treated with oral retinoid 20 mg/d for 3 weeks and 10 mg/d for next 3 weeks with concurrent topical steroid, and most lesions disappeared completely with post inflammatory hyperpigmentation. No evidence of recurrence has been observed during 3 months of followup.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Artritis Reumatoide
/
Psoriasis
/
Recurrencia
/
Piel
/
Biopsia
/
Enfermedad de Crohn
/
Estudios de Seguimiento
/
Factor de Necrosis Tumoral alfa
/
Hiperpigmentación
/
Dermatitis
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
Límite:
Adolescente
/
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Dermatology
Año:
2012
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS